Form 4: OptiNose CFO Terry Kohler Receives Stock and Option Grants

OptiNose CFO Terry Kohler was granted 150,000 restricted stock units and options to purchase 675,000 shares of common stock on October 7, 2024.

Summary

• On October 7, 2024, Terry Kohler, the Chief Financial Officer of OptiNose, Inc., received a grant of 150,000 restricted stock units (RSUs).
• These RSUs vest over a four-year period, with 25% vesting on October 7, 2025, and the remainder vesting in equal quarterly installments over the subsequent three years, contingent upon continued service with OptiNose.
• Each RSU represents the right to receive one share of OptiNose common stock.
• Kohler also received an option to purchase 675,000 shares of OptiNose common stock at an exercise price of $0.71 per share.
• This option also vests over a four-year period, with 25% vesting on October 7, 2025, and the remainder vesting in equal monthly installments over the following three years, subject to continued service.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, which is generally viewed neutrally to positively as it aligns management interests with shareholders. The vesting schedule promotes long-term commitment.

Positives

• The grants of RSUs and stock options to the CFO align his interests with those of the shareholders, incentivizing him to work towards the company's long-term success.
• The vesting schedules encourage continued service and commitment from the CFO.

Future Outlook

The vesting schedules for the RSUs and stock options are contingent upon continued service with the Issuer, suggesting an expectation of continued employment for the CFO.

Industry Context

Grants of stock options and restricted stock units are common compensation practices for executives in publicly traded companies, aligning their interests with those of shareholders and incentivizing long-term value creation.

Comparison to Industry Standards

• Stock option and RSU grants are standard practice for executive compensation in the pharmaceutical industry.
• Vesting schedules of four years are also typical to ensure long-term commitment.
• The specific number of shares and exercise price would need to be compared to similar companies of OptiNose's size and stage to determine if they are in line with industry standards.

Stakeholder Impact

• Shareholders may view the grants positively as they incentivize the CFO to improve company performance.
• Employees may see the grants as a sign of the company's commitment to its leadership.

Key Dates